First clinical evidence for bubonic plague treatment
Researchers from the UK and Madagascar, in collaboration with Madagascar’s health services and national plague programme, have conducted the world’s first rigorous clinical trial of treatments for bubonic plague.
The IMASOY trial provides the first robust evidence of the efficacy and safety of two common treatment regimens.
They found that a ten-day course of oral antibiotic ciprofloxacin is a highly effective and safe alternative to existing treatment with injectable antibiotic requiring hospitalisation.
Though cases have been declining, plague remains a high-threat pathogen of pandemic potential. Most continents see sporadic cases of bubonic plague every year, with Madagascar reporting approximately 80% of global cases.
Several treatment options are included in the current international and national guidelines, but regulatory approval has been based solely on animal studies and human safety data.
In the IMASOY trial, patients were randomly allocated to receive either a ten-day oral regimen of ciprofloxacin, or a regimen requiring three days’ injectable gentamicin followed by seven days’ ciprofloxacin (intravenous therapy).
A total of 450 patients with clinically suspected bubonic plague were enrolled between 2020-2024 at 47 sites in 11 districts in Madagascar and treated with either regimen. Of these, 222 plague infections were confirmed by laboratory testing.
Both regimens were found to be highly effective and safe, with overall treatment success rates of about 90% and an overall mortality rate of about 4%.
Piero Olliaro, Professor at the Pandemic Science Institute, University of Oxford and senior author of the study, said: “Despite its deadly history, we’ve had little clinical evidence on treating bubonic plague—until now. Thanks to the patients and healthcare workers in the trial, we now have real-world proof of effective, safe treatment. Ongoing data analysis will deepen our understanding of the disease, including risk factors, symptoms, and diagnostics.”
Diana Turner, Senior Digital Content Editor, DDW
